The Diabetes Market Outlook: Market analysis of future growth and leading players by sector

Executive summary

Epidemiology analysis

Global diabetes market analysis

Insulin market analysis

Oral antidiabetic (OAD) market analysis

Leading players in the diabetes market

Chapter 1 Epidemiology analysis

Summary

Introduction

Disease description

Type 1 diabetes

Type 2 diabetes

Current and future prevalence of diabetes

Diagnosis

Fast-track review for diabetes drugs

Current and future treatment patterns

Insulin prescribing

TZD prescribing

Chapter 2 Global diabetes market analysis

Summary

Introduction

History of antidiabetic drugs

Current growth drivers

Insulins

TZDs

Combination therapies

Future growth drivers

Non-injected insulin

Inhaled insulins

Oral insulins

Insulin patches

Dual PPAR agonists

GLP-1 agonists and DPP IV inhibitors

GLP-1 agonists

DPP IV inhibitors

Amylinomimetic agents

Chapter 3 Insulin market analysis

Summary

Introduction

Insulin categories and sales

Company market share

Brand market share and sales

Human Insulins

Brand analysis

Humulin (human insulin)

NovoLin (human insulin)

Fast-acting human insulin analogs

Brand analysis

Humalog (insulin lispro)

NovoLog (insulin aspart)

Apidra (insulin glulisine)

Long-acting insulin analogs

Brand analysis

Lantus (insulin glargine)

Levemir (insulin detemir)

Chapter 4 Oral antidiabetic (OAD) market

analysis

Summary

Introduction

OAD categories and sales

Company market share

Sulfonylurea products

Brand market share and sales

Brand analysis

Amaryl (glimepriride)

Glucotrol XL (glipizide)

Biguanide products

Brand market share and sales

Brand analysis

Glucophage & Glucophage XR (metformin)

Combined sulfonylurea & biguanide products (and other combination

therapies)

Sulfonylurea + biguanide single-pill combination drugs

Glucovance (glyburide + metformin)

TZD + other OAD single-pill combination therapies

Thiazolidinedione (TZD) products

Brand market share and sales

Brand analysis

Drug analysis

Actos (pioglitazone)

Avandia (rosiglitazone)

Avandamet (rosiglitazone + metformin)

Alpha glucosidase inhibitor (AGI) products

Brand market share and sales

Brand analysis

Precose/Glucobay (acarbose)

Basen (voglibose)

Glyset/Diastabol (miglitol)

Other OAD products (the prandial glucose regulators)

Brand market shares and sales

Brand analysis

Prandin/NovoNorm (repaglinide)

Starlix (nateglinide)

Chapter 5 Leading players in the diabetes

market

Summary

Introduction

Eli Lilly

Therapeutic focus

Insulin market share

Marketed products

R&D pipeline

Exenatide (synthetic exendin-4)

Ruboxistaurin

Pulmonary insulin (AIR)

Oralin

LY-818 (naveglitazar)

Novo Nordisk

Therapeutic focus

Insulin market share

Marketed products

R&D pipeline

NovoMix 50 and 70 (NN1185): Injectable insulin formulations

AERx iDMS (NN1998): An inhaled insulin

Liraglutide (NN2211)

Sanofi-Aventis

Therapeutic focus

Insulin and OAD market shares

R&D pipeline

Exubera

DiaPep277

Takeda

Therapeutic focus

OAD market share

Marketed products

R&D pipeline

Actos/metformin combination

ATL-962

TAK-559

TAK-654

TAK-428

GlaxoSmithKline

Therapeutic focus

OAD market share

Marketed products

R&D pipeline

Avandaryl

Avandamet XR

HIM-2

677954

Bristol-Myers Squibb

Therapeutic focus

OAD market share

Marketed products

R&D pipeline

Muraglitazar

Basulin

Inhaled Insulin

Pfizer

Therapeutic focus

Marketed products

R&D pipeline

Exubera

Novartis

Therapeutic focus

Marketed products

R&D pipeline

LAF237

Merck KGaA

Therapeutic focus

Marketed products

R&D pipeline

Index

List of Figures

Figure 1.1: Prevalence of obese and overweight adults in US, 1976-2000

Figure 1.2: Proportion of type 2 diabetics diagnosed, 2003

Figure 1.3: Management of type 2 diabetes by physician type, 2003

Figure 1.4: Proportion of drug treated type 2 diabetics treated with insulin in monotherapy or combination, 2003

Figure 2.5: Development timeline for antidiabetic drug classes, 1920-2004

Figure 2.6: Overview of diagnosis rates, treatment rates and insulin prescribing trends in six major markets, 2003

Figure 2.7: Approved combination therapies for type 2 diabetes, 2003

Figure 2.8: Positive and negative developments influencing the antidiabetics market, 2004 & forwards

Figure 2.9: Overview of the non-invasive insulin pipeline, 2004

Figure 3.10: Insulin brands by company and type, 2004

Figure 3.11: US/European market share of leading insulins (%), 1999-2003

Figure 3.12: Humulin SWOT analysis

Figure 3.13: NovoLin SWOT analysis

Figure 3.14: Humalog SWOT analysis

Figure 3.15: NovoLog SWOT analysis

Figure 3.16: Apidra SWOT analysis

Figure 3.17: Lantus SWOT analysis

Figure 3.18: Levemir SWOT analysis

Figure 4.19: Sales of OAD categories in Europe and US ($m), 2003

Figure 4.20: Global market share of leading sulfonylureas (%), 1999-2003

Figure 4.21: Amaryl SWOT analysis

Figure 4.22: Glucotrol XL SWOT analysis

Figure 4.23: Global market share of leading biguanides, 1999-2003

Figure 4.24: Glucophage XR SWOT analysis

Figure 4.25: Glucovance SWOT analysis

Figure 4.26: US/European market share of leading TZDs (%), 1999-2003

Figure 4.27: Actos SWOT analysis

Figure 4.28: Avandia SWOT analysis

Figure 4.29: Avandamet SWOT analysis

Figure 4.30: US/European market share of leading AGIs (%), 1999-2003

Figure 4.31: Precose/Glucobay SWOT analysis

Figure 4.32: Basen SWOT analysis

Figure 4.33: US/European market share of leading PGRs (%), 1999-2003

Figure 4.34: Prandin/NovoNorm SWOT analysis

Figure 4.35: Starlix SWOT analysis

Figure 5.36: Eli Lilly s therapeutic focus, 2003-2010

Figure 5.37: Novo Nordisk s therapeutic focus, 2003 and 2010

Figure 5.38: Sanofi-Aventis  therapeutic focus, 2003 & 2010

Figure 5.39: Takeda s therapeutic focus, 2003 & 2010

Figure 5.40: GSK s therapeutic focus, 2003 & 2010

Figure 5.41: BMS s changing therapeutic focus, 2003-2010

Figure 5.42: Pfizer s changing therapeutic focus, 2003-10

Figure 5.43: Merck KGaA s changing therapeutic focus, 2003 & 2010

List of Tables

Table 1.1: Prevalence of Type 2 diabetes (m), 2003-2012

Table 1.2: US and European Sales by Drug Class ($m), 2002-2003

Table 2.3: US/European sales category totals ($m), 2002-2003

Table 3.4: US/European Sales of insulins by category ($m), 2002-2003

Table 3.5: Insulin market share by company and territory (%), 2002-2003

Table 3.6: Sales of leading insulins by country ($m), 2002-2003

Table 3.7: Branded human insulins

Table 3.8: Branded fast-acting human insulin analogs

Table 3.9: Branded long-acting human insulin analogs

Table 4.10: Frequency and level of dose of OADs

Table 4.11: US/European OAD category market share (%), 2002-2003

Table 4.12: US/European OAD Market Share by Company (%), 2002-2003

Table 4.13: Sales of leading sulfonylureas by country ($m), 2002-2003

Table 4.14: Branded sulfonylureas

Table 4.15: Sales of leading biguanides by country ($m), 2002-2003

Table 4.16: Branded biguanides

Table 4.17: Proportion of patients receiving monotherapy versus combination therapy treatment (%), 2003

Table 4.18: US/European sales of sulfonylurea + biguanide single-pills ($m), 1999-2003

Table 4.19: Sales of leading TZDs by country ($m), 2002-2003

Table 4.20: Branded TZDs

Table 4.21: Sales of leading AGIs by country ($m), 2002-2003

Table 4.22: Branded AGIs

Table 4.23: Sales of leading PGRs by country (%), 2002-2003

Table 4.24: Branded PGRs

Table 5.25: US/European diabetes market share by company (%), 2002-2003

Table 5.26: US Insulin Market Share by Company (%), 2002-2003

Table 5.27: US/European sales of Eli Lilly s marketed diabetes portfolio ($m), 2002-2003

Table 5.28: Projected sales of Eli Lilly s diabetes R&D pipeline ($m), 2007 & 2010

Table 5.29: European insulin market share by company (%), 2002-2003

Table 5.30: US/European sales of Novo Nordisk s marketed diabetes portfolio ($m), 2002-2003

Table 5.31: Projected sales of Novo Nordisk s diabetes R&D pipeline ($m), 2007 & 2010

Table 5.32: US/European sales of Sanofi-Aventis  marketed diabetes portfolio ($m), 2002-2003

Table 5.33: Projected sales of Sanofi-Aventis  diabetes R&D pipeline ($m), 2003 & 2010

Table 5.34: US/European sales of Takeda s marketed diabetes portfolio ($m), 2002-2003

Table 5.35: Projected sales of Takeda s diabetes R&D pipeline ($m), 2007 & 2010

Table 5.36: US/European sales of GSK s marketed diabetes portfolio, 2002-2003

Table 5.37: GSK s diabetes R&D pipeline, 2003

Table 5.38: US OAD Market Share by Company (%), 2002-2003

Table 5.39: US/European sales of BMS s diabetes portfolio, 2002-2003

Table 5.40: Projected sales of BMS s diabetes R&D pipeline ($m), 2007 & 2010

Table 5.41: Projected sales of Merck KGaA s diabetes R&D pipeline ($m), 2007 & 2010